Dilatation of the bridging cerebral cortical veins in childhood hydrocephalus suggests a malfunction of venous impedance pumping.
Autorzy:
Bateman GA; Department of Medical Imaging, John Hunter Hospital, Locked Bag 1, Newcastle Region Mail Center, Newcastle, NSW, 2310, Australia. .; Newcastle University Faculty of Health, Callaghan Campus, Newcastle, NSW, Australia. . Bateman AR; School of Mechanical Engineering, University of New South Wales, Sydney, NSW, Australia. SubramanianGM; Department of Paediatric Neurology, John Hunter Hospital, Newcastle, NSW, Australia.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jul 29; Vol. 12 (1), pp. 13045. Date of Electronic Publication: 2022 Jul 29.
The incidence of obesity, venous sinus stenosis and cerebral hyperaemia in children referred for MRI to rule out idiopathic intracranial hypertension at a tertiary referral hospital: a 10 year review.
Autorzy:
Bateman GA; Department of Medical Imaging, John Hunter Hospital, Newcastle Region Mail Center, Locked Bag 1, Newcastle, NSW, 2310, Australia. .; Newcastle University Faculty of Health, Callaghan Campus, Newcastle, NSW, Australia. . SubramanianGM; Paediatric Neurology, John Hunter Hospital, Newcastle, NSW, Australia. Yap SL; Department of Medical Imaging, John Hunter Hospital, Newcastle Region Mail Center, Locked Bag 1, Newcastle, NSW, 2310, Australia. Bateman AR; Biomedical Engineering, University of NSW, Sydney, NSW, Australia.
Pokaż więcej
Źródło:
Fluids and barriers of the CNS [Fluids Barriers CNS] 2020 Sep 29; Vol. 17 (1), pp. 59. Date of Electronic Publication: 2020 Sep 29.
The incidence of significant venous sinus stenosis and cerebral hyperemia in childhood hydrocephalus: prognostic value with regards to differentiating active from compensated disease.
Autorzy:
Bateman GA; Department of Medical Imaging, Newcastle Region Mail Center, John Hunter Hospital, Locked Bag 1, Newcastle, NSW, 2310, Australia. .; Newcastle University Faculty of Health, Callaghan Campus, Newcastle, NSW, Australia. . Yap SL; Department of Medical Imaging, Newcastle Region Mail Center, John Hunter Hospital, Locked Bag 1, Newcastle, NSW, 2310, Australia. SubramanianGM; Department of Paediatric Neurology, John Hunter Hospital, Newcastle, NSW, Australia. Bateman AR; Biomedical Engineering, University of NSW, Sydney, NSW, Australia.
Pokaż więcej
Źródło:
Fluids and barriers of the CNS [Fluids Barriers CNS] 2020 Apr 29; Vol. 17 (1), pp. 33. Date of Electronic Publication: 2020 Apr 29.
Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.
Autorzy:
Agarwal K; Institute of Liver Studies, Kings College Hospital, London, UK. Ahn SH; Brain Korea 21 Project of Medical Science, Yonsei University College of Medicine, Seoul, Korea. Elkhashab M; Toronto Liver Centre, Toronto, ON, Canada. Lau AH; Gilead Sciences, Inc., Foster City, CA, USA. Gaggar A; Gilead Sciences, Inc., Foster City, CA, USA. Bulusu A; Gilead Sciences, Inc., Foster City, CA, USA. Tian X; Gilead Sciences, Inc., Foster City, CA, USA. Cathcart AL; Gilead Sciences, Inc., Foster City, CA, USA. Woo J; Gilead Sciences, Inc., Foster City, CA, USA. SubramanianGM; Gilead Sciences, Inc., Foster City, CA, USA. Andreone P; Center for the Study and Research on Hepatitis, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. Kim HJ; Chung-Ang University Hospital, Seoul, South Korea. Chuang WL; Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Nguyen MH; Stanford University Medical Center, Palo Alto, CA, USA.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2018 Nov; Vol. 25 (11), pp. 1331-1340. Date of Electronic Publication: 2018 Aug 22.
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Autorzy:
Asselah T; Department of Hepatology, Hôpital Beaujon, APHP, INSERM CRI, UMR1149, University Paris-Diderot, Clichy, France. Bourgeois S; Campus Stuivenberg, Antwerp, Belgium. Pianko S; Monash Health and Monash University, Clayton, Vic., Australia. Zeuzem S; Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany. Sulkowski M; Johns Hopkins University, Baltimore, MD, USA. Foster GR; Queen Mary University London, London, UK. Han L; Gilead Sciences Inc., Foster City, CA, USA. McNally J; Gilead Sciences Inc., Foster City, CA, USA. Osinusi A; Gilead Sciences Inc., Foster City, CA, USA. Brainard DM; Gilead Sciences Inc., Foster City, CA, USA. SubramanianGM; Gilead Sciences Inc., Foster City, CA, USA. Gane EJ; Auckland Clinical Studies Ltd, Auckland, New Zealand. Feld JJ; Toronto Centre for Liver Disease, Toronto, ON, Canada. Mangia A; Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.
Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease.
Autorzy:
Gharib AM; National Institute of Diabetes and Digestive and Kidney Diseases, Biomedical and Metabolic Imaging Branch, Bethesda, MD, USA. Han MAT; National Institute of Diabetes and Digestive and Kidney Diseases, Liver Diseases Branch, Bethesda, MD, USA. Meissner EG; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.; Critical Care Medicine Department, NIH Clinical Center, AIDS Section, Bethesda, MD, USA.; Division of Infectious Diseases, Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA. Kleiner DE; Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA. Zhao X; National Institute of Diabetes and Digestive and Kidney Diseases, Office of the Director, Bethesda, MD, USA. McLaughlin M; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. Matthews L; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. Rizvi B; National Institute of Diabetes and Digestive and Kidney Diseases, Liver Diseases Branch, Bethesda, MD, USA. Abd-Elmoniem KZ; National Institute of Diabetes and Digestive and Kidney Diseases, Biomedical and Metabolic Imaging Branch, Bethesda, MD, USA. Sinkus R; Biomedical Engineering, Imaging Sciences and Biomedical Engineering Division, Kings College, London, UK. Levy E; Interventional Radiology, NIH Clinical Center, Bethesda, MD, USA. Koh C; National Institute of Diabetes and Digestive and Kidney Diseases, Liver Diseases Branch, Bethesda, MD, USA. Myers RP; Gilead Sciences, Inc., Foster City, CA, USA. SubramanianGM; Gilead Sciences, Inc., Foster City, CA, USA. Kottilil S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. Heller T; National Institute of Diabetes and Digestive and Kidney Diseases, Liver Diseases Branch, Bethesda, MD, USA. Kovacs JA; Critical Care Medicine Department, NIH Clinical Center, AIDS Section, Bethesda, MD, USA. Morse CG; Critical Care Medicine Department, NIH Clinical Center, AIDS Section, Bethesda, MD, USA.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2017; Vol. 2017, pp. 2067479. Date of Electronic Publication: 2017 Apr 05.
Whole Genome Sequencing Identifies a 78 kb Insertion from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3.
Autorzy:
Brewer MH; Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia.; Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia. Chaudhry R; Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia.; Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia. Qi J; Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia.; Discipline of Pathology, University of Sydney, Camperdown, New South Wales, Australia. Kidambi A; Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia. Drew AP; Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia. Menezes MP; The Institute for Neuroscience and Muscle Research, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.; T.Y. Nelson Department of Neurology and Neurosurgery, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.; Paediatrics and Child Health, University of Sydney, Camperdown, New South Wales, Australia. Ryan MM; Department of Neurology, Royal Children's Hospital, Parkville, Victoria, Australia.; Murdoch Childrens Research Institute, Parkville, Victoria, Australia.; Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia. Farrar MA; Department of Neurology, Sydney Children's Hospital, Randwick, New South Wales, Australia.; School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Kensington, New South Wales, Australia. Mowat D; School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Kensington, New South Wales, Australia.; Department of Medical Genetics, Sydney Children's Hospital, Randwick, New South Wales, Australia. SubramanianGM; Department of Paediatrics, John Hunter Children's Hospital, Newcastle, New South Wales, Australia. Young HK; Department of Paediatrics, Royal North Shore Hospital, St Leonards, New South Wales, Australia.; Northern Clinical School, Sydney Medical School, University of Sydney, St Leonards, New South Wales, Australia.; Department of Neurogenetics, The Children's Hospital at Westmead, Westmead, New South Wales, Australia. Zuchner S; John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, United States of America.; Dr. John T. Macdonald Department of Human Genetics, University of Miami Miller School of Medicine, Miami, Florida, United States of America. Reddel SW; Department of Neurology, Concord Repatriation General Hospital, Concord, New South Wales, Australia. Nicholson GA; Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia.; Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.; Molecular Medicine, Concord Repatriation General Hospital, Concord, New South Wales, Australia. Kennerson ML; Northcott Neuroscience Laboratory, ANZAC Research Institute, Concord, New South Wales, Australia.; Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.; Molecular Medicine, Concord Repatriation General Hospital, Concord, New South Wales, Australia.
Pokaż więcej
Źródło:
PLoS genetics [PLoS Genet] 2016 Jul 20; Vol. 12 (7), pp. e1006177. Date of Electronic Publication: 2016 Jul 20 (Print Publication: 2016).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
Autorzy:
Sandborn WJ; Robarts Clinical Trials, University of Western Ontario, London, ON, Canada.; University of California, San Diego, CA, USA. Bhandari BR; Delta Research Partners, LLC, Monroe, LA, USA. Fogel R; Clinical Research Institute of Michigan, LLC, Chesterfield, MI, USA. Onken J; Duke University Medical Center, Durham, NC, USA. Yen E; Gilead Sciences, Inc., Foster City, CA, USA. Zhao X; Gilead Sciences, Inc., Foster City, CA, USA. Jiang Z; Gilead Sciences, Inc., Foster City, CA, USA. Ge D; Gilead Sciences, Inc., Foster City, CA, USA. Xin Y; Gilead Sciences, Inc., Foster City, CA, USA. Ye Z; Gilead Sciences, Inc., Foster City, CA, USA. French D; Gilead Sciences, Inc., Foster City, CA, USA. Silverman JA; Gilead Sciences, Inc., Foster City, CA, USA. Kanwar B; Gilead Sciences, Inc., Foster City, CA, USA. SubramanianGM; Gilead Sciences, Inc., Foster City, CA, USA. McHutchison JG; Gilead Sciences, Inc., Foster City, CA, USA. Lee SD; University of Washington, Seattle, WA, USA. Shackelton LM; Robarts Clinical Trials, University of Western Ontario, London, ON, Canada. Pai RK; Mayo Clinic Arizona, Scottsdale, AZ, USA. Levesque BG; Robarts Clinical Trials, University of Western Ontario, London, ON, Canada. Feagan BG; Robarts Clinical Trials, University of Western Ontario, London, ON, Canada.; Department of Medicine, University of Western Ontario, London, ON, Canada.; Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada.
A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
Autorzy:
King TH; GlobeImmune, Inc., Louisville, Colorado, United States of America. Kemmler CB; GlobeImmune, Inc., Louisville, Colorado, United States of America. Guo Z; GlobeImmune, Inc., Louisville, Colorado, United States of America. Mann D; GlobeImmune, Inc., Louisville, Colorado, United States of America. Lu Y; GlobeImmune, Inc., Louisville, Colorado, United States of America. Coeshott C; GlobeImmune, Inc., Louisville, Colorado, United States of America. Gehring AJ; Molecular Microbiology and Immunology & Saint Louis University Liver Center, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America; Agency for Science, Technology and Research (A*STAR), Singapore Institute for Clinical Sciences, Singapore, Singapore. Bertoletti A; Agency for Science, Technology and Research (A*STAR), Singapore Institute for Clinical Sciences, Singapore, Singapore. Ho ZZ; Agency for Science, Technology and Research (A*STAR), Singapore Institute for Clinical Sciences, Singapore, Singapore. Delaney W; Gilead Sciences Inc., Foster City, California, United States of America. Gaggar A; Gilead Sciences Inc., Foster City, California, United States of America. SubramanianGM; Gilead Sciences Inc., Foster City, California, United States of America. McHutchison JG; Gilead Sciences Inc., Foster City, California, United States of America. Shrivastava S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America. Lee YJ; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America. Kottilil S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America. Bellgrau D; GlobeImmune, Inc., Louisville, Colorado, United States of America; Integrated Department of Immunology, University of Colorado School of Medicine, Aurora, Colorado, United States of America. Rodell T; GlobeImmune, Inc., Louisville, Colorado, United States of America. Apelian D; GlobeImmune, Inc., Louisville, Colorado, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 Jul 22; Vol. 9 (7), pp. e101904. Date of Electronic Publication: 2014 Jul 22 (Print Publication: 2014).
Typ publikacji:
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.
Changes in B-lymphocyte stimulator protein levels during treatment with albinterferon alfa-2b in patients with chronic hepatitis C who have failed previous interferon therapy.
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
